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Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric,
adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the
chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590
MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the
MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identiﬁed. All patients were
classiﬁed according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia
patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different
MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to
be predominantly associated with illegitimate recombinations of the MLL gene (B90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL,
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MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all
clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are
presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
Leukemia (2013) 27, 2165–2176; doi:10.1038/leu.2013.135
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INTRODUCTION
Chromosomal rearrangements involving the human MLL (mixed
lineage leukemia) gene are recurrently associated with the disease
phenotype of acute leukemias.1,2 The presence of distinct MLL
rearrangements is an independent dismal prognostic factor,
while very few MLL rearrangements display either a good or
intermediate outcome.3,4 It became also clear from recent studies
that the follow-up of patients during therapy by minimal
residual disease (MRD) monitoring has a very strong impact on
outcome.5–7 For this purpose, we established a diagnostic network
that allowed different study groups and clinical centers to obtain
genomic MLL breakpoint sequences that can be directly used
for quantifying MRD levels in patients. The current work ﬂow to
identify MLL rearrangements includes a prescreening step
(cytogenetic analyses,8,9 split-signal ﬂuorescence in situ hybridi-
zation10–12 or reverse transcription-polymerase chain reaction
(PCR) in combination with long-distance inverse-PCR that was
performed on small amounts (B1 mg) of isolated genomic
DNA.13 This allowed us to identify readily reciprocal translo-
cations, complex chromosomal rearrangements, gene-internal
duplications, deletions or inversions on chromosome 11q, and
MLL gene insertions into other chromosomes, or vice versa, the
insertion of chromatin material into the MLL gene.
To gain insight into the frequency of distinct MLL rearrange-
ments, all prescreened samples of infant, pediatric and adult
leukemia patients was sent for analysis to the Frankfurt Diagnostic
Center of Acute Leukemia (DCAL). Prescreening tests were
performed at different European centers (Aarhus, Berlin, Bordeaux,
Bratislava, Brest, Bristol, Catania, Copenhagen, Frankfurt, Giessen,
Granada, Graz, Grenoble, Haifa, Hamburg, Hanover, Heidelberg,
Jena, Jerusalem, Kiel, Lille, Lisbon, Madrid, Minsk, Montpellier,
Monza, Munster, Munich, Nancy, Nantes, Newcastle upon Tyne,
Olomouc, Padua, Paris, Porto, Prague, Reims, Rotterdam, Tampere,
Tel Hashomer, Toulouse, Turku, Tubingen, Vienna, Yekaterinburg,
Zabrze and Zurich) and centers located outside of Europe (Boston,
Buenos Aires, Hong Kong, Houston, Rio de Janeiro, Seoul, Sydney
and Tohoku), where acute leukemia patients are enrolled in
different study groups. All prescreened MLL rearrangements were
successfully analyzed at the Frankfurt DCAL and patient-speciﬁc
MLL fusion sequences for MRD monitoring were obtained.
On the basis of the results obtained in this and previous
studies,13–15 a total of 79 direct translocation partner genes (TPGs)
and their speciﬁc breakpoint regions have now been identiﬁed.
Seven additional loci have been cloned where the 50-portion of
MLL was not fused to another gene. In 19 other cases, we were not
able to identify a der(11) fusion gene. This could be either
attributed to a technical problem (such as a too long genomic
fragment) or to the fact that no der(11) exists in these few
patients. However, in all of these 19 cases, we successfully
identiﬁed a reciprocal MLL fusion allele. The latter subgroup was
allocated to the group of ‘complex MLL rearrangements’ (n¼ 182)
because of the extending class of ‘reciprocal MLL fusion genes’
(63 loci, 119 fusion genes). Finally, there were still 35 chromosomal
translocations of the human MLL gene that were characterized in
the past by cytogenetic methods, but that were never analyzed at
the molecular level. Thus, the MLL recombinome presently
comprises 121 different ‘direct TPGs’ (decoding the MLL N
terminus), whereas the 182 ‘reciprocal TPGs’ (decoding the MLL
C terminus) derive from complex rearrangements that involved
already known ‘direct TPGs’. It is worth noting that in nearly all of
the investigated cases the 30-MLL gene portion was not lost,
except the very few cases (n¼ 4 out of 1622) that were interstitial
deletions at 11q23 causing a direct fusion of the 50-MLL gene
portion with a gene portion localized telomeric to MLL, or where
we were able to demonstrate that only an MLL spliced fusion
exists (n¼ 3 out of 1622). Besides the number of direct and
reciprocal MLL fusions, we tried to analyze all available patient
data for interesting association between age, sex, disease type,
secondary leukemia and breakpoint localization. All these data
and their analyses is here presented and discussed.
PATIENTS AND METHODS
Patient material
Genomic DNA was isolated from bone marrow and/or peripheral blood
samples of leukemia patients and sent to the DCAL (Frankfurt/Main,
Germany). Patient samples were obtained from study groups (the AMLCG-
study group, Munich; the GMALL study group, Berlin; Polish Pediatric
Leukemia and Lymphoma Study Group; Zabrze; I-BFM network) or other
diagnostic centers (Aarhus, Berlin, Bordeaux, Boston, Bratislava, Brest,
Bristol, Buenos Aires, Catania, Copenhagen, Frankfurt, Giessen, Granada,
Graz, Grenoble, Haifa, Hamburg, Hanover, Heidelberg, Hong Kong, Houston,
Jena, Jerusalem, Kiel, Lille, Lisbon, Madrid, Minsk, Montpellier, Monza,
Munster, Munich, Nancy, Nantes, Newcastle upon Tyne, Olomouc, Padua,
Paris, Porto, Prague, Reims, Rio de Janeiro, Rotterdam, Seoul, Sydney,
Tampere, Tel Hashomer, Tohoku, Toulouse, Turku, Tubingen, Vienna,
Yekaterinburg, Zabrze and Zurich). Informed consent was obtained from
all patients or patients’ parents/legal guardians and control individuals.
Long distance inverse-PCR experiments
All DNA samples were treated and analyzed as described.13–15 Brieﬂy, 1mg
genomic patient DNA was digested with restriction enzymes and religated
to form DNA circles before long-distance inverse-PCR analyses. Restriction
polymorphic PCR amplimers were isolated from the gel and subjected to
DNA sequence analyses to obtain the patient-speciﬁc fusion sequences.
This genomic DNA fusion sequence is idiosyncratic for each leukemia
patient and was made available to the sender of the DNA sample. The
average processing time was around ﬁve working days.
Data evaluation and statistical analyses
All clinical and experimental patient data were implemented into a database
program (FileMaker Pro) for further analysis. Information about all individual
patients was used to compare all deﬁned subgroups and to perform statistical
analyses to retrieve important information or signiﬁcant correlations. w2 Tests
were performed to identify signiﬁcant deviations from mean values.
RESULTS
The study cohort
To analyze the recombinome of the human MLL gene, 1622
prescreened acute leukemia samples were obtained from
the above-mentioned centers over a period of one decade
(2003–2013). Successful analysis of the direct MLL fusion could be
performed for all patient samples except 19 cases, where only a
reciprocal MLL fusion allele could be characterized. In these cases
we identiﬁed only the reciprocal MLL fusion allele to guarantee
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MRD experiments. Of those 1622 cases, 1590 entered this study
because we obtained all the critical information that was
necessary for data processing (gender, age at diagnosis, disease
type and subtype or information about de novo or secondary
leukemia). A total of 32 cases was excluded from our study
because relevant information about these patients were missing;
they had the following MLL rearrangements: 9 MLL-MLLT3/AF9;
5 MLL-AFF1/AF4; 4 MLL-MLLT1/ENL; 4 MLLMLLT10/AF10,
3 MLL-MLLT4/AF6, 2 MLL-MLLT6/AF17, 1 MLL-GAS7, 1
MLL-EPS15, 1 MLL-LOC100128568, 1 LOC387646-MLL and 1
MLL-partial tandem duplication (PTD). The exclusion of these 32
patients did not interfere with the general conclusions made in
this study.
Age distribution according to clinical subtypes
We ﬁrst analyzed our cohort according to the age at diagnosis.
As displayed in Figure 1, the age distribution is quite similar to the
expected age distribution known from different cancer registries.
Acute lymphocytic leukemia (ALL) incidence has a peak at the age
of 2–3 years, and then decreases with age and increases again in
older adults. Acute myeloid leukemia (AML) patients display a
small peak at 2 years, decline and then steadily increases with age.
For the purpose of our study, we separated our cohort into an
‘infant acute leukemia group’ (0–12 months; n¼ 558: 440 ALL, 105
AML, 13 N/A), a ‘pediatric acute leukemia group’ (13 months–18
years; n¼ 416: 205 ALL, 202 AML, 9 N/A) and an ‘adult acute
leukemia patient’ group (418 years; n¼ 616: 333 ALL, 272 AML,
11 N/A). As shown in Figure 1, we also added information
about therapy-induced leukemia (TIL; n¼ 77). Thirty-three patients
could not be simply categorized into ‘ALL’ or ‘AML’ because
they received other diagnoses (MLL¼ 18; myelodysplastic
syndrome¼ 5, primary myeloﬁbrosis¼ 1; lymphoma¼ 2) or
because we had simply no informations from the corresponding
center (unknown disease type¼ 7).
Identiﬁcation of MLL rearrangements and their distribution in
clinical subgroups
The most frequent MLL rearrangements in these six subgroups
were summarized in Figure 2. Infant ALL patients (n¼ 440)
displayed 216 t(4;11)(q21;q23) involving the AFF1/AF4 gene, 73
t(9;11)(p22;q23) involving the MLLT3/AF9 gene, 96 t(11;19)
(q23;p13.3) involving the MLLT1/ENL gene, 22 t(10;11)(p12;q23)
involving the MLLT10/AF10 gene, 1 t(6;11)(q27;q23) involving the
MLLT4/AF6 gene, 12 t(1;11)(p32;q23) involving the EPS15 gene and
20 other MLL rearrangements (9p13.3, 9p22, AFF4/AF5, DCP1A/
SACM1L, AFF3/LAF4 (2 ), BTBD18, N/A (9 ), PICALM, PRPF19,
EEFSEC and TRNC18).
Infant AML patients (n¼ 105) displayed 2 t(4;11)(q21;q23)
involving the AFF1/AF4 gene, 23 t(9;11)(p22;q23) involving the
MLLT3/AF9 gene, 1 t(11;19)(q23;p13.3) involving the MLLT1/ENL
gene, 28 t(10;11)(p12;q23) involving the MLLT10/AF10 gene, 18
t(11;19)(q23;p13.1) involving the ELL gene, 3 t(6;11)(q27;q23)
involving the MLLT4/AF6 gene, 1 t(1;11)(p32;q23) involving the
EPS15 gene and 29 other MLL rearrangements (11q24, ABI1, ABI2,
MLLT11/AF1Q (7 ), FLNA (2 ), FNBP1, GAS7, KIAA1524, MYO1F
(3 ), N/A (3 ), NEBL, NRIP3, PICALM, SEPT6 (3 ) and SEPT9 (2 )).
Pediatric ALL patients (n¼ 205) displayed 97 t(4;11)(q21;q23)
involving the AFF1/AF4 gene, 37 t(9;11)(p22;q23) involving the
MLLT3/AF9 gene, 40 t(11;19)(q23;p13.3) involving the MLLT1/
ENL gene, 4 t(10;11)(p12;q23) involving the MLLT10/AF10 gene,
5 t(6;11)(q27;q23) involving the MLLT4/AF6 gene, 4 t(1;11)
(p32;q23) involving the EPS15 gene and 18 other MLL rearrange-
ments (1p32, 21q22, MLLT6/AF17, BCL9L, FOXO3 (2 ), AFF3/LAF4
(3 ), MAML2 (2 ), N/A (2 ), PICALM, RUNDC3B, SEPT5, SEPT11
and TRNC18).
Figure 1. Age distribution of investigated patients. The age distribution of all analyzed patients (n¼ 1690) is summarized. (Upper part)
Diagram displaying ALL and AML patients. Age at diagnosis was for infants (0–1 year), pediatric (1–18 years) and adult patients (418 years).
The number of ALL, AML and other patients is listed below. We also added the information about TIL patients, the number of complex MLL
rearrangements (CL) and specified the ‘Non-ALL’ and ‘Non-AML’ patients (MLL, myelodysplastic syndrome (MDS), primary myelofibrosis
(PMF) and unknown) in more detail for each age group. The precise number of patient cases summarized on the right.
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Pediatric AML patients (n¼ 202) displayed 2 t(4;11)(q21;q23)
involving the AFF1/AF4 gene, 73 t(9;11)(p22;q23) involving the
MLLT3/AF9 gene, 10 t(11;19)(q23;p13.3) involving the MLLT1/
ENL gene, 40 t(10;11)(p12;q23) involving the MLLT10/AF10 gene,
19 t(11;19)(q23;p13.1) involving the ELL gene, 2 MLL PTDs,
19 t(6;11)(q27;q23) involving the MLLT4/AF6 gene, 3 t(1;11)
(p32;q23) involving the EPS15 gene and 34 other MLL rearrange-
ments (11q23.3, ABI1 (2 ), ACACA, ACTN4, MLLT6/AF17 (2 ),
MLLT11/AF1Q (4 ), ARHGEF17, BUD13, CASC5, LAMC3, NA (3 ),
SEPT2, SEPT5, SEPT6 (6 ), SEPT9 (5 ), SEPT11, TET1 and VAV1).
Adult ALL patients (n¼ 333) displayed 274 t(4;11)(q21;q23)
involving the AFF1/AF4 gene, 6 t(9;11)(p22;q23) involving the
MLLT3/AF9 gene, 37 t(11;19)(q23;p13.3) involving the MLLT1/ENL
gene, 1 t(10;11)(p12;q23) involving the MLLT10/AF10 gene,
1 t(11;19)(q23;p13.1) involving the ELL gene, 1 MLL PTD, 6 t(6;11)
(q27;q23) involving the MLLT4/AF6 gene, 1 t(1;11)(p32;q23)
involving the EPS15 gene, and 6 other MLL rearrangements
(11q23 (2 ), ACTN4, CEP164 and TET1 (2 )).
Adult AML patients (n¼ 272) displayed 3 t(4;11)(q21;q23)
involving the AFF1/AF4 gene, 71 t(9;11)(p22;q23) involving the
MLLT3/AF9 gene, 12 t(11;19)(q23;p13.3) involving the MLLT1/ENL
gene, 20 t(10;11)(p12;q23) involving the MLLT10/AF10 gene,
29 t(11;19)(q23;p13.1) involving the ELL gene, 64 MLL PTDs, 33
t(6;11)(q27;q23) involving the MLLT4/AF6 gene, 4 t(1;11)(p32;q23)
involving the EPS15 gene and 36 other MLL rearrangements
(MLLT6/AF17 (7 ), MLLT11/AF1Q (2 ), AKAP13, AP2A2, ARHGEF12,
C2CD3, CASP8AP2, CBL, DCPS, GMPS, CEP170B (2 ), ME2, MYH11,
NA, PDS5A, PICALM, SEPT5, SEPT6 (2 ), SEPT9 (5 ), SMAP1, TET1
(2 ) and TOP3A). All these data are summarized in Table 1.
On the basis of the above distribution, about 95% of all ALL
patients (n¼ 978) were characterized by the fusion genes MLL-
AFF1/AF4 (B60.0%), MLL-MLLT1/ENL (B17.7%), MLL-MLLT3/AF9
(B11.9%), MLL-MLLT10/AF10 (B2.8%), MLL-EPS15 (B1.7%) and
MLL-MLLT4/AF6 (B1.2%), respectively. About 84% of all AML
patients (n¼ 579) were characterized by the fusion genes
MLL-MLLT3/AF9 (B28.8%), MLL-MLLT10/AF10 (B15.2%), MLL-ELL
(B11.4%), MLL PTDs (B11.4%), MLL-MLLT4/AF6 (B9.5%), MLL-
MLLT1/ENL (B4.0%), MLL-SEPT6 (B1.9%) and MLL-MLLT6/AF17
(B1.6%), respectively. This updates recently published data on the
frequency and distribution of different MLL fusion partner
genes.15–17
Breakpoint distribution according to clinical subtypes
We also investigated the distribution of chromosomal breakpoints
within the MLL breakpoint cluster region in all investigated clinical
subgroups. Brieﬂy, the breakpoint cluster region is localizing
between MLL exon 9 and MLL intron 11, where the majority of
Figure 2. Classification of patients according to age classes and disease type. (Top) Frequency of most frequent TPGs in the investigated
patient cohort of MLL-rearranged acute leukemia patients (n¼ 1590). This patient cohort was divided into ALL (left) and AML patients (right).
Gene names are written in black, and percentages are indicated as white numbers. Thirty-three patients could not be classified into the ALL or
the AML disease types, respectively. (Middle) TPG frequencies for the infant, pediatric and adult patient group. (Bottom) Subdivision of all
three age groups into ALL and AML patients. Negative numbers confer again to the number of patients who were neither classified to the
‘ALL’ nor to the ‘AML’ subgroup.
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Table 1. Overview about all investigated TPGs
Direct TPG Infant Pediatric Adult Total
ALL AML Other ALL AML Other ALL AML Other
AFF1/AF4 216 2 4 97 2 2 274 3 — 600
MLLT3/AF9 73 23 2 37 73 3 6 71 3 291
MLLT1/ENL 96 1 2 40 10 1 37 12 — 199
MLLT10/AF10 22 28 2 4 40 1 1 20 2 120
ELL — 18 — — 19 — 1 29 1 68
PTD — — — — 2 — 1 64 1 68
MLLT4/AF6 1 3 — 5 19 — 6 33 — 67
EPS15 12 1 1 4 3 — 1 4 — 26
MLLT11/AF1Q — 7 — — 4 — — 2 — 13
SEPT9 — 2 — — 5 — — 5 — 12
SEPT6 — 3 — — 6 — — 2 — 11
MLLT6/AF17 — — — 1 2 — — 7 — 10
NA 9 3 1 2 3 1 19
AFF3/LAF4 2 — — 3 — — — — — 5
TET1 — — — — 1 — 2 2 — 5
PICALM 1 1 — 1 — — — 1 — 4
ABI1 — 1 — — 2 — — — — 3
CASC5 — — — — 1 — — — 2 3
MYO1F — 3 — — — — — — — 3
SEPT5 — — — 1 1 — — 1 — 3
ACTN4 — — — — 1 — 1 — — 2
FLNA — 2 — — — — — — — 2
FOXO3 — — — 2 — — — — — 2
CEP170B — — — — — — — 2 — 2
MAML2 — — — 2 — — — — — 2
SEPT11 — — — 1 1 — — — — 2
TNRC18 1 — — 1 — — — — — 2
ABI2 — 1 — — — — — — — 1
ACACA — — — — 1 — — — — 1
AFF4/AF5 1 — — — — — — — — 1
AKAP13 — — — — — — — 1 — 1
AP2A2 — — — — — — – 1 — 1
ARHGEF12 — — – — – — — 1 — 1
ARHGEF17 — — — — 1 — — — — 1
BCL9L — — — 1 — — — — — 1
BUD13 — — — — 1 —— — — — 1
C2CD3 — — — — — — — 1 — 1
CASP8AP2 — — — — — — — 1 — 1
CBL — — — — — — — 1 — 1
CEP164 — — — — — — 1 — — 1
CREBBP — — — — — 1 — — — 1
DCP1A 1 — — — — — — — — 1
DCPS — — — — — — — 1 — 1
FNBP1 — 1 — — — — — — — 1
GAS7 — 1 — — — — — — — 1
GMPS — — — — — — — 1 — 1
KIAA1524 — 1 — — — — — — — 1
LAMC3 — — — — 1 — — — — 1
LOC100131626 — — — — — — — — 1 1
BTBD18 1 — — — — — — — — 1
ME2 — — — — — — — 1 — 1
MYH11 — — — — — — — 1 — 1
NEBL — 1 — — — — — — — 1
NRIP3 — 1 — — — — — — — 1
PDS5A — — — — — — — 1 — 1
PRPF19 1 — — — — — — — — 1
RUNDC3B — — — 1 — — — — — 1
EEFSEC/SELB 1 — — — — — — — — 1
SEPT2 — — — — 1 — — — — 1
SMAP1 — — — — — — — 1 — 1
TOP3A — — — — — — — 1 — 1
VAV1 — — — — 1 — — — — 1
1p13.1 — — — — — — — — 1 1
1p32 (EPS15) — — 1 1 — — — — — 2
9p13.3 1 — — — — — — — — 1
9p22 (MLLT3/AF9) 1 — — — — — — — — 1
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patients had their individual breakpoints (n¼ 1530). Only sixty
patients (3.8%) had their breakpoint outside of the major
breakpoint cluster region (see Supplementary Table S1).
Of interest, recently published clinical studies put a new focus
on chromosomal breakpoint localization: the distribution
of chromosomal breakpoints within the MLL breakpoint cluster
region was correlated with the outcome of MLL-rearranged
leukemia patients.18 Basically, the outcome of leukemia patients
with breakpoint in MLL intron 11 was worse compared to those
patients with upstream breakpoints. A rational explanation for this
observation came from the PHD1–3 domain, which is encoded by
MLL exons 11–16. This domain confers oligomerization19 and was
described to bind to the CYP33/PPIE protein.20,21 In addition, the
PHD3 domain binds either to CYP33/PPIE or to methylated lysine-
4 residues of histone H3.22 Binding of PHD3 to H3K4me2/3 peptides
is greatly enhanced by the adjacent bromo-domain,23 but CYP33/
PPIE represents a prolyl-peptidyl isomerase and performs a
cis–trans isomerization of the proline-1665 residue. This cis-to-
trans conversion is mutual exclusive with H3K4me2/3 binding by
the PHD3 domain. By contrast, a CYP33/PPIE-bound PHD3 enables
binding to BMI1 and associated repressor proteins (HDAC/CBX4/
KDM5B), and thus switches the human MLL protein from a
transcriptional activator/maintenance factor to a transcriptional
repressor. It is worth noting that the adjacent bromo-domain
binds to ASB2 and triggers the degradation of MLL.24 Similarly, a
recent publication demonstrated that the PHD2 domain also binds
another E3 ligase, named CDC34, which controls again the steady-
state stability of the MLL protein.25
Breakpoints upstream of MLL exon 11 will not alter the domain
structure and the associated functions of the PHD1–3 domain,
whereas breakpoints within MLL exon 11 or intron 11 will
deﬁnitively destroy this cysteine–histidine-rich domain, most likely
because of an alternative protein fold.18 This will have several
effects on the functions of the resulting fusion proteins, like for
example, losing the oligomerization capacity, an increased fusion
protein stability or losing the ability to switch into a transcriptional
repressor (CYP33-BMI1/HDAC/CBX4/KDM5B).26 As this should
impact cancer biology and clinical behavior, we started to
analyze the breakpoint distribution for all clinical subgroups and
compared them with the mean distribution observed for all
1590 patients. We decided not to use a random distribution of
breakpoints because this will be based only on the length of each
DNA region, but will not take into account that the speciﬁc
chromatin features of MLL intron 11 that is highly sensitive against
cytotoxic drugs, exhibits a DNase1 hypersensitive site,27 an
apoptotic cleavage site,28 an RNA polymerase II binding site29
and several topoisomerase II binding sites.30
For our analyses, we subdivided the MLL breakpoint cluster
region into three subregions: (A) exon 9–intron 9¼ 1761 bp;
(B) exon 10–intron 10¼ 679 bp; and (C) intron 11–intron
12¼ 4929 bp. The observed ‘mean breakpoint frequencies’ for
these three regions were A¼ 38.5%, B¼ 19.5% and C¼ 38.7% for
all 1530 patients listed in Supplementary Table S1.
As shown in Figure 3, we ﬁrst subcategorized all patient cases
according to their origin. We had 70 samples from North and
South American states, 1403 samples from European countries
and 117 cases from Russia, Asian countries or the Australian
continent. When analyzing the breakpoint frequencies for A–C, it
became obvious that the majority of patients in Europe display a
breakpoint distribution that was nearly identical to the mean
breakpoint frequencies mentioned above. The South American
patient group was very young and displayed a nonsigniﬁcant
tendency to MLL intron 11 breakpoints (43.5% vs 37.4%), whereas
the Russian/Asian/Australian group displayed a shift towards
breakpoints localizing within MLL intron 11 (50.43% vs 37.4%,
P¼ 0.138). This could neither be attributed to the mean age nor to
a higher rate for secondary malignancies (6% vs 5% in Europe). Of
interest, all 77 cases of our cohort that were classiﬁed as therapy-
induced leukemia (TIL) displayed a breakpoint distribution of
A¼ 33.8%, B¼ 9.5% and C¼ 54.1%. Thus, even when a controlled
exposition to drugs was causing an MLL rearrangement, only a
maximum of 54% MLL intron 11 breaks could be reached. As this is
the ﬁrst description of such a phenomenon and we are
missing demographic controls, we cannot draw any conclusions
about a putative environmental or maternal exposition
during pregnancy that would explain such a shift towards MLL
intron 11 recombinations. However, when we analyzed this
phenomenon in more detail (see Supplementary Table S2), we
realized some remarkable differences in certain countries that are
even gender speciﬁc. Currently, we have no explanations for the
observed differences, but future research may help to unravel this
phenomenon.
Another observation concerning the breakpoints localization
became obvious, when we analyzed breakpoint distributions
together with TPGs. As shown in Supplementary Table S3,
recombinations affecting MLLT4/AF6 and MLLT10/AF10 display a
tendency for MLL intron 9 breaks rather than MLL intron 11 breaks
(MLLT4/AF6, Po0.0001; MLLT10/AF10, P¼ 0.006). This was quite
different for AFF1/AF4 and MLLT1/ENL recombinations where MLL
intron 11 breaks seem to be favored (Pp0.0001). As already
described above, the biological properties of the MLL PHD1–3
domain depends on the MLL breakpoint. Thus, all fusions
occurring within MLL introns 9 and 10 will result in fusion proteins
that are still able to oligomerize and to be controlled in its steady-
state abundance like the wild-type MLL protein. Vice versa,
recombination within MLL intron 11 will result in fusion proteins
that could neither be degraded efﬁciently nor can be switched
into transcriptional repressor proteins.
Table 1. (Continued )
Direct TPG Infant Pediatric Adult Total
ALL AML Other ALL AML Other ALL AML Other
11q23 — — — — — — 2 — — 2
11q23.3 — — — — 1 — — — — 1
11q24 — 1 — — — — — — — 1
21q22 — — — 1 — — — — — 1
Xq26.3 (CT45A2) — — — — — 1 — — — 1
Sum 440 105 13 205 202 9 333 272 11 1590
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; DCAL, Diagnostic Center of Acute Leukemia. All fusion genes that have been
analyzed at the DCAL and their distribution between infant, pediatric and adult leukemia patients are shown. Total numbers are given for each patient group
separate in ALL, AML and other diseases. The most frequent fusion partner genes were separated from the gene that has been isolated less frequently.
The MLL recombinome
C Meyer et al
2170
Leukemia (2013) 2165 – 2176 & 2013 Macmillan Publishers Limited
These ﬁndings also suggest that oligomerization capacity
or binding to certain PHD domain-interacting proteins may be
quite important for the oncogenic function exerted by MLL fusion
proteins. In addition, the breakpoint distribution in infant and
adult patients changes signiﬁcantly: infants display a higher rate of
MLL intron 11 breakpoints (Po0.0001), whereas adults display a
higher rate of MLL intron 9 breakpoints (P¼ 0.009). These ﬁndings
could not be attributed to the number of cases with secondary
malignancies (TIL) or any other parameter, which we listed. These
data underscore the importance of the precise breakpoint
localization that may—dependent on the involved fusion partner
gene—inﬂuence even the outcome of patients.18
Novel TPGs
Apart from the many new MLL fusion genes that have already
been discovered at the DCAL and published in the past years
(see Supplementary Table S4; n¼ 26), we present additional eight
novel TPGs: RUNDC3B (Run domain-containing protein 3B; 483
amino acids), AP2A2 (adaptor protein complex AP-2 subunit a-2;
939 amino acids), PRPF19 (pre-mRNA processing factor; 504 amino
acids); BUD13 (619 amino acids), CEP164 (centrosomal protein;
1460 amino acids), AKAP13 (A kinase-anchoring protein (PKA
associated), ARHGEF13; 2813 amino acids), MYH11 (myosin heavy
chain 11; 1938 amino acids) and ME2 (malic enzyme 2, NAD(þ )-
dependent, mitochondrial (malate to pyruvate conversion);
584 amino acids).
The RUNDC3B protein has been described to bind to RAP2,31
a RAS adaptor protein, which has distinct roles in cell adhesion
and cell migration. AP2A2 interacts with the mutant form of
Huntingtin and alters the kinetic of aggregate formation, thereby
functioning as chaperone.32 PRPF19, also named PRP19 or SNEV,
was described to be part of large protein complexes involved in
pre-mRNA processing,33 DNA repair,34 regulation of proteasomal
degradation35 and was also described as ‘senescence evasion
factor’.36 For BUD13 no functional data are available. CEP164 is a
centrosomal protein that binds to XPA and is required for
UV-dependent DNA repair.37 Upon DNA damage, CEP164
becomes phosphorylated by ATM/ATR at the serine-186
residue.38 AKAP13, also known as AKAP-Lbc, represents a Rho-
GEF that is regulated by LC3/MAP1LC3A, an important protein for
autophagy.39 It has been described to be involved into the signal
pathway from TLR2 to NFKB140 and to enhance the cAMP-
controlled activation of ERK1/2.41 MYH11 is a smooth muscle
myosin gene that has been identiﬁed through chromosomal
rearrangements with CBFB. These inv(16) AML patients express
the CBFB–MYH11 fusion protein that is highly oncogenic.42 Finally,
ME2 is a nuclear-encoded mitochondrial enzyme that converts
malate into pyruvate.
The MLL recombinome
Within the past 22 years, many genetic aberrations involving the
human MLL gene located on chromosome 11 band q23 have been
described. Seventy-nine TPGs out of 121 are now characterized at
the molecular level (see Supplementary Table S4 and Table 1).
Forty-ﬁve MLL fusion genes have been described by others,
whereas 34 TPGs have been ﬁrst identiﬁed at the Frankfurt DCAL.
Figure 3. World distribution of patients. (Top) Worldmap grossly dividing the investigated patients into three distinct subgroups: American,
European and Asian countries. The number of investigated patients is shown and the contribution of individual countries is given in patient
numbers. Each country is indicated by its international country code. (Below) Information about the patient cohort. Mean age, age range and
the amount of infants (I), pediatric (P) and adult patients (A) is indicated. In addition, we added the amount of therapy-induced malignancies
in number and percentage. The breakpoint distribution for each subgroup within MLL exon 9/intron 9, MLL exon 10/intron 10 and MLL exon
11/intron 11 is displayed. Red mark in MLL intron 11: fragile site within MLL that is sensible to exogenous drug exposure.
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Additional seven loci are presented here, where neither a direct
fusion partner gene nor a ‘spliced fusion’ could be identiﬁed.
Spliced fusions have been described in cases where the 50-portion
of the MLL gene (exons 1–9) is fused with the upstream region of
another intact gene. In most of these cases, the last MLL exon
splices to the second exon of this downstream located gene.
Examples for this type of mechanism have already been
described,15 but will also be discussed below. Finally, additional
35 genetic loci were identiﬁed by cytogenetics but not further
characterized. All yet characterized TPGs and the appropriate
citation references were summarized in Supplementary Table S4.
Genetic alterations resulting in genetic rearrangements of the
human MLL gene
In general, human MLL rearrangements are initiated by a
DNA damage situation, which induces DNA repair via the
non-homologous-end-joining DNA repair pathway.43,44 Genetic
recombinations involving the human MLL gene are predominantly
the result of ‘reciprocal chromosomal translocations’ (n¼ 51; see
Figure 4). On the basis of our analyses and the literature, reciprocal
recombinations lead to fusions of the 50-MLL gene portion
with the following TPGs: ABI1, ABI2, ACTN4, AFF1/AF4, AKAP13,
ARHGAP26, ARHGEF17, ASAH3, CASC5/AF15Q14, CASP8AP2,
CEP170B, CREBBP, DAB2IP, DCP1A/SACM1L, EEFSEC/SELB, ELL,
EP300, EPS15, FOXO3, FOXO4, FRYL, GAS7, GMPS, GPHN, KIAA1524,
LAMC3, LASP1, LPP, MAPRE1, ME2, MLLT1/ENL, MLLT3/AF9, MLLT4/
AF6, MLLT6/AF17, MLLT11/AF1Q, MYO1F, MYH11, NCKIPSD, NEBL,
PDS5A, RUNDC3B, SACM1L, SEPT2, SEPT5/PNUTL, SEPT9, SEPT11,
SH3GL1, SMAP1, TET1/LCX, TNRC18 and TOP3A, respectively.
Gene-internal PTDs of speciﬁc MLL gene portions (duplication of
MLL gene segments coding either for introns 2–9, 2–11, 4–9, 4–11
or 3–8) are frequently observed in AML patients.45 MLL PTDs
mediate dimerization of the MLL N terminus, a process that seems
to be sufﬁcient to mediate leukemogenic transformation.46 We
have observed MLL PTDs in 2 patients within the group of
pediatric AML, 1 patient within the group of adult ALL and 65
patients within the group of adult AML. This demonstrates that
MLL PTDs are predominantly detected in adult AML patients, in
line with previously published data.47
MLL recombinations involving only chromosome 11 are based
on two independent DNA strand breaks that are accompanied
either by inversions or deletions on 11p or 11q (Inv, Del). Several
recombinations have been characterized that belong to these two
groups. MLL fusions to AP2A2, BTBD18, BUD13, C2CD3,
LOC100131626, MAML2, NRIP3, PICALM and PRPF19 are based on
the inversion of a chromatin portion of 11p or 11q, leading to
reciprocal MLL fusions. By contrast, a deletion on chromosome 11
fuses the 50-portion of MLL directly to another gene located
further downstream (ARHGEF12, BCL9L, CBL and CEP164). In few
cases, we observed that the 30-truncated MLL is located upstream
of another, intact gene. In that case, we could demonstrate an
‘MLL spliced fusion’, which means that the last exon of the MLL
gene splices directly to the second exon of the further down-
stream gene. This has been observed for the MLL-DCPS fusion.
Beside the above-mentioned DCPS gene, other genes have been
identiﬁed that can transcriptionally fuse to 50-MLL sequences.
These were ZFYVE19, and also the MLL fusion partners like AFF1/
AF4, CT45A2, ELL, EPS15, MLLT3/AF9, MLLT4/AF6, MYO1F and SEPT5.
In case of MLLT1/ENL, about 50% of all recombination events were
spliced fusions,48 and for MLL-EPS15 fusions about 30%. Spliced
fusions to AFF1/AF4, CT45A2, DCPS, ELL, MLLT3/AF9, MLLT4/AF6,
MYO1F, SEPT5, ZFYVE19 and SEPT5 represent very rare events.
Beside reciprocal chromosomal translocations of MLL, MLL PTDs
and 11p/q rearrangements (Del and Inv), additional genetic
rearrangements were identiﬁed in the genomic DNA of analyzed
leukemia samples. While the previous rearrangements are based
on two independent DNA strand breaks, all other genetic events
observed for the MLL gene represent more complex rearrange-
ments with at least three or more DNA double-strand breaks.
In these cases, the expected reciprocal MLL fusion gene cannot be
detected, because other sequences will be fused to the 30-portion
of the MLL gene.
Complex MLL rearrangements are best represented by ‘three-
way chromosomal translocations’ involving three independent
chromosomes and resulting in three different fusion genes.
More complex is a mechanism that we referred to ‘chromosomal
fragment insertions’. Either a fragment of chromosome 11
(including portions of the MLL gene) is inserted into another
chromosome (Ins1), or vice versa, a fragment of another
chromosome (including portions of a TPG) is inserted into the
breakpoint cluster region of the MLL gene (Ins2). An insertion
mechanism is required in those cases where the transcriptional
orientation of a given TPG is not identical to the transcriptional
orientation of the MLL gene. The MLL gene is transcribed
in telomeric direction. TPGs with a transcriptional orientation in
direction to the centromer are predominantly recombining with
MLL by such a chromatin insertion mechanism. These genes are
ACACA, AFF3/LAF4, AFF4/AF5, CENPK/FKSG14, FLNA, FNBP1,
LOC100128568, MLLT10/AF10, SARNP, SEPT6, SORBS2/ARGBP2 and
VAV1. In all these events at least three independent fusion genes
will be generated. The most prominent gene frequently involved
in the latter mechanism is the MLLT10/AF10 gene (see below).
Finally, even more complex rearrangements may occur when
‘chromothripsis’ comes into play. Chromothripsis has been
identiﬁed as novel mechanism that generates many fusion
alleles in a single event upon a single-cell division (for a review
see Holland and Cleveland49).
Reciprocal MLL fusions
From two recent papers it became clear that reciprocal MLL fusion
proteins may have an important role for cancer development.50,51
Therefore, we also put emphasis on the analyses of complex MLL
rearrangements. These 182 patient cases had three-way or
four-way translocations resulting in more than two fusion alleles.
From these 182 cases, 63 were identiﬁed to carry a single 30-MLL
gene portion that was not fused to any upstream gene (only non-
coding loci were identiﬁed). By contrast, 119 reciprocal gene
fusions were identiﬁed from which 80% were out-of-frame fusions.
Only 24 reciprocal MLL fusion genes with in-frame fused exons
were identiﬁed, being capable of expressing the C-terminal
portion of the MLL protein under the control of promoters that
derive from reciprocal fusion partner genes (n¼ 24; ACER1,
ADARB2, APBB1IP, ATG16L2, CEP164 (2 ), DENND4A, FLJ46266,
GNA12, GPSN2, LOC10013227, LRRTM4, , MYO18A, , N-PAC, NFKB1,
NKAIN2, PIUP4K2A, RABGAP1L, RNF115, SCAF8, SEPT8, SEPT5, TRIP4,
UVRAG and WNK2). In all other cases (n¼ 158), the 30-MLL gene
portion was fused either to no gene (n¼ 63; 1p36, 1q25, 3 1q32,
2p12, 2p13, 2p16, 2 2p21, 2q11.2, 3p23.3, 4p14, 2 4q12, 4q13,
6 4q21, 4q22, 4q27, 2 4q28, 5q23, 6p21, 6q27, 7p14, 7q22, 8p21,
9p13, 9p21, 9p23, 10p12, 10p15, 11p11, 11p15, 11q12, 11q13,
2 11q14, 11q21, 3 11q22, 9 11q23, 12p13, 15q13, 17q11.2,
19q12, 20q11.2 and 2 22q13) or to genes in an out-of-frame or a
head-to-head manner (n¼ 119; ADSS, ANTXR2, ARCN1, ARHGAP12,
BMP2K, BTN3A1, BUD13, C18orf25, CACNA1B, CACNB2, CCDC33,
CDK14, CMAH, CRLF1, CRTAC1, CUGBP1, DHX16, DLG2, DNAH6,
DNAJA1, DNAJC1, DOCK5, DSCAML1, DSCAML1, ELF2, EPYC, ETV6,
FCHSD2, FXYD2, FXYD6, GRIA4, GRIP1, GTDC1, HELQ, HK1,
IKZF1, KDM2A, 2 KIAA0999, KIAA1239, LMO2, LOC100506746,
LOC390877, LOC441179, LPXN, LRBA, MALAT1, MCL1, MDM1, MED1,
MEF2A, MEF2C, MMP13, MPZL2, MPZL3, NCAM1, NDUFS3, NRG3,
NT5C2, PARP14, PBRM1, PBX1, PDE6C, PHLDB1, PITPNA, PIWIL4,
RDH5, RNF25, RPS3, SCGB1D1, SCN3B, SEC14L1, SFRS4, SGK1,
SLC43A3, SNAPC3, SORL1, 2 SVIL, TCF12, TIMM44, TLN1,
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TMEM123, TMEM135, TNRC6B, TNRC6C, TNXB, TPTE2P5, TUBGCP2,
UBASH3B, UBE4A, UNC84A, USP20, WDTC1 and ZNF57).
As summarized in Supplementary Table S5, a total of 20
different genes were identiﬁed that were involved in these
complex rearrangements (ABI1 (1/3), MLLT10/AF10 (41/120), MLLT6/
AF17 (1/10), MLLT11/AF1Q (4/13), AFF1/AF4 (49/600), AFF4/AF5 (1/1),
MLLT4/AF6 (6/67), MLLT3/ AF9 (25/291), ELL (4/68), MLLT1/ENL
(16/199), EPS15 (2/26), AFF3/LAF4 (2/2), LOC100131626 (1/1), MYO1F
(2/3), PICALM (1/4), SEPT6 (3/11), SEPT9 (1/12), TNRC18 (1/1) VAV1
(1/1) and Xq26 (1/1)). The 30-portion of these TPGs were regularly
fused to the 50-portion of MLL, whereas the above-mentioned 182
loci or genes were fused to the 30-portion of the MLL gene. The
latter fusions are termed ‘reciprocal TPGs’ and are summarized in
Supplementary Table S5. In all cases where the 30-portion of the
MLL gene was fused either to a chromosomal locus (non-coding)
or in an out-of-frame manner to another gene, one would argue
that no transcript is being made. However, the 30-portion of the
MLL is by itself sufﬁcient to produce its own mRNA (starting at the
MLL intron 11 to exon12 borderline), which can be translated into
the MLL* protein.29 This MLL* protein starts at a bona ﬁde AUG
start codon encoded by MLL exon 18, which results in a protein
beginning within the MLL BD domain and ending at the end of
the SET domain. The MLL* protein is processed by Taspase1 and
results in a 97 kDa MLL*-N and an MLL-C protein fragment. This
shorter version of MLL (B235 kDa) loses all functions of the
N-terminal portion, whereas functions of the C-terminal portion
are retained (for example, H3K4 HMT activity).
Additional 19 MLL rearrangements have been characterized
where we could not identify the direct MLL fusion partner gene.
However, in all 19 cases we were able to isolate the reciprocal
MLL fusion alleles (1q25, 1q32, 7q22, 9p21, 11p11, 11q21, 11q23,
CRTAC1, DNAJA1, DSCAML1, KDM2A, RNF115, RNF25, SEPT5, SORL1,
USP20, WDTC1 and ZNF57). Only 2 of these 19 cases displayed
an in-frame fusion to the 30-MLL portion (RNF115-MLL and
SEPT5-MLL), whereas all the others had solely the intact 3-portion
of MLL left to express the MLL* protein (see Supplementary
Table S5).
DISCUSSION
Here, we present an update of the ‘MLL recombinome’ associated
with different hematologic malignancies, and in particular with
acute leukemia (ALL and AML). All our analyses were performed by
using small amounts of genomic DNA that were isolated from
bone marrow or peripheral blood samples (n¼ 1622) of leukemia
patients. In some cases, we analyzed cDNA from a given patient to
validate the presence of MLL spliced fusions, or to investigate
alternative splice products generated from the investigated MLL
fusion genes. The results of this study allow to draw several
conclusions.
The applied long-distance inverse-PCR technique allowed to
identify direct and reciprocal MLL fusions, MLL gene-internal
duplications, chromosome 11 inversions, chromosomal 11 dele-
tions and the insertion of chromosome 11 material into other
chromosomes, or vice versa, the insertion of chromatin material of
other chromosomes into the MLL gene (see Figure 4). Moreover,
we successfully extended our knowledge by analyzing more cases
with complex MLL rearrangements. During the latter analyses, a
large collection of reciprocal MLL fusions was identiﬁed. About
15% represent in-frame fusions that can be readily expressed into
a reciprocal fusion protein. All other characterized reciprocal
MLL alleles represented out-of-frame fusions with either a
Figure 4. General recombination mechanism and associated TPGs. (Top) Genes are categorized either by reciprocal chromosomal
translocation (rCTL; n¼ 51), spliced fusion (Spl; n¼ 3), inversions at 11p/q (Inv; n¼ 9), insertions (Ins1 and Ins2; n¼ 12) or 11q deletions
(Del; n¼ 4). (Bottom) All identified recombination events, arranged according to the number of DNA double-strand breaks (DSBs) necessary to
explain the recombination event. Green: Chromosome 11; red and orange: partner chromosomes involved in the recombination process.
Green vertical bars: MLL; red, orange, blue and pink vertical bars: partner genes involved in recombination events; derivative 11 chromosomes
is always depicted by ‘Der’. Black and white horizontal lines: recombination sites on wild-type and derivative chromosomes. rCTL: reciprocal
chromosomal translocation; Del/Inv: deletion/inversion; 3 W-CTL: three-way chromosomal translocation; CTLþD: chromosomal translocation
including deletion(s); Ins1: chromosomal fragment including portions of the MLL gene is inserted into a partner chromosome; Ins2:
chromosomal fragment including portions of a partner gene is inserted into the MLL gene; cCTL: complex chromosomal translocations, for
example, by chromothripsis.
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chromosomal locus or a reciprocal TPG, but even these events
allow to transcribe and express a 50-truncated MLL protein, termed
MLL*.29 This shorter version of MLL has no ability to bind Menin1,
LEDGF or MYB, but still carries all enzymatic functions necessary
to carry out H4K16 acetylations by the associated MOF protein or
H3K4 methylation by the SET domain complex.
The analysis of 1622 MLL fusion alleles led to the discovery of
34 novel TPGs in the past 10 years, of which 26 have already
been described (see Supplementary Table S4). Eight TPGs are
completely new and have not been published yet. Taken together
with 45 MLL fusions that have been described by others
(see Supplementary Table S4), we can present today a total
of 79 ‘direct MLL fusions’ that have been characterized at
the molecular level. All these MLL fusions provide a rich source
for future analyses of oncogenic MLL protein variants.
According to our data, the seven most frequent rearrangements
of the MLL gene occur either with TPGs like AFF1/AF4, MLLT3/AF9,
MLLT1/ENL, MLLT10/AF10, ELL, MLLT4/AF6 or derive from gene-
internal duplications (MLL-PTDs). Their occurrence differed
signiﬁcantly in the cohorts of infant, pediatric and adult leukemia
patients. We also observed tendencies that correlate speciﬁc
gene fusions with sex or age at diagnosis. Examples were that
MLLT3/AF9 (P¼ 0.080), MLLT10/AF10 (P¼ 0.019) and MLL-PTDs
(P¼ 0.065) occur more frequently in the male group of patients,
whereas the female patients were more affected by MLL-AFF1/AF4
fusions (P¼ 0.015). The most striking ﬁnding was that breakpoint
distributions differ signiﬁcantly when concerning distinct TPGs
and age groups. It is well known that breakpoints in infants occur
more frequently in MLL intron 11. We could validate this ﬁnding
for MLL-AFF1/AF4 and MLL-MLLT1/ENL fusions, but observed a
completely contrary situation in case of MLL-MLLT10/AF10 fusions.
Quite surprising was the breakpoint distribution for MLL-AF6
fusions that displayed a clear preference for MLL intron
9 recombinations. Again, these deviations from the observed
mean breakpoint distribution are an argument for differences
in the biology of the resulting fusion proteins with respect
to oligomerization or factor binding dependency. This has to be
investigated in more detail in the future to understand these
observations.
An important translational aspect of this study is the
establishment of patient-speciﬁc DNA sequences that can be used
for monitoring MRD by quantitative PCR techniques. Owing to
the fact that a given MLL fusion allele is genetically stable
and a monoallelic marker for each tumor cell, a more reliable
quantiﬁcation and tracing of residual tumor cells becomes
possible. For each of these 1622 acute leukemia patients at least
one MLL fusion allele was identiﬁed and characterized by
sequencing. Several prospective studies were already initiated
and ﬁrst published data veriﬁed the reliability of these genomic
markers for MRD monitoring.4 Therefore, the use of these MRD
markers will contribute in the future to a better stratiﬁcation
of leukemia patients, which will help to further improve the
outcome.
The analysis of the MLL recombinome allows to classify MLL
fusion partner genes into functional categories. As discussed
above, only very few TPGs are recurrently identiﬁed in different
individuals, and moreover, with a signiﬁcant frequency. On
the basis of this study, these TPGs are AFF1/AF4, MLLT3/AF9,
MLLT1/ENL, MLLT10/AF10 and MLLT4/AF6. At least for the AFF1/
AF4, MLLT3/AF9, MLLT1/ENL and MLLT10/AF10 protein exists a
functional correlation, as all these proteins are organized within a
protein complex (or different subcomplexes) that affect transcrip-
tional elongation. AF4 is the docking platform for AF9 or ENL,
which both interact (via MLLT10/AF10) to DOT1L.52,53 DOT1L
enable methylation of lysine-79 residues of histone H3 proteins, a
prerequisite for the maintenance of RNA transcription.54,55
AF4 binds with its N-terminal portion to the P-TEFb kinase
that phosphorylates the largest subunit of RNA polymerase II,
DSIF, the NELF complex and UBE2A. This converts RNA POL A into
POL E and allows gene transcription.56 As a result, increased and
Figure 5. Common pathways of the most frequent MLL fusions. The four most frequent MLL fusions, MLL-ENL, MLL-AF9, MLL-AF10 and
AF4-MLL, are either interacting directly with the AF4 complex or are mimicking the AF4 complex in case of AF4-MLL. The crucial components
within the AF4 complex are the P-TEFb kinase and the H3K79 HMT DOT1L protein. Hyperactive AF4 or AF4-MLL is strongly enhances
the transcriptional processes. In addition, changes in the steady-state AF4 complex stability is causing extended H3K79me2/3 signatures.
Future inhibitory strategies are indicated in red.
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extended H3K79 methylation signatures seem to accompany
the presence of several fusion proteins (MLL-AFF1/AF4, AFF1/
AF4-MLL, MLL-MLLT3/AF9, MLL-MLLT1/ENL, MLL-MLLT10/AF10
and MLL-MLLT4/AF6),57 whereas an additional increase in H3K4
methylation was only demonstrated by the presence of the
reciprocal AFF1/AF4-MLL56 that causes pro-B ALL in C57Bl6 mice50
and was shown to cooperate with the RUNX1 protein.58 Thus, all
the major MLL fusions share a common pathway, which is not only
functionally related but offers new and interesting venues to
develop new drugs against this leukemias, for example, by the
development of DOT1L inhibitors.59 This shared pathway and the
effects of certain MLL fusion protein on basic transcription and on
the epigenetic layer are summarized in Figure 5. The fusion
proteins MLL-MLLT1/ENL, MLL-MLLT3/AF9 and MLL-MLLT10/AF10
recruit thereby the AFF1/AF4 complex, whereas the reciprocal
AFF1/AF4-MLL fusion protein is able to perform exactly the same
actions on RNA polymerase II and DOT1L. Thus, future therapies
addressing either the inhibition of DOT1L, P-TEFb or blocking
the interaction of the MLL N terminus with MENIN1/LEDGF/MYB
are promising new ways to address these leukemias. In addition,
the inhibition of Taspase1 would help to inactivate the AFF1/AF4-
MLL fusion protein, as the uncleaved fusion protein is rapidly
degraded by SIAH1 and SIAH2.60
In summary, MLL rearrangements are associated with poor
outcome in pediatric and adult acute leukemia. As outlined above,
the systematic analysis of the MLL recombinome allows one to
draw conclusions on certain aspects of the hematomalignant
transformation processes. We also present additional information
as Supplementary data ﬁles (see Supplementary Tables S6–8),
which contain general information about the investigated
patient cohort, the analyzed T-ALL cases (n¼ 36) and the TIL
cases (n¼ 77). Our efforts to analyze the MLL recombinome will
be continued and provided as free-of-charge service to any
collaborators.
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